• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Alector Inc (NQ: ALEC )

    4.920 +0.110 (+2.29%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 480,397
    Open 4.860
    Bid (Size) 4.930 (4)
    Ask (Size) 4.940 (11)
    Prev. Close 4.810
    Today's Range 4.770 - 5.010
    52wk Range 3.660 - 8.900
    Shares Outstanding 83,351,778
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)
    From Alector, Inc.
    Via GlobeNewswire
    Alector to Participate in Upcoming Healthcare Conferences
    From Alector, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -38.42%
    -38.42%
    1 Month
    -6.99%
    -6.99%
    3 Month
    +8.37%
    +8.37%
    6 Month
    -18.27%
    -18.27%
    1 Year
    -25.45%
    -25.45%

    More News

    Read More
    Alector Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Alector, Inc.
    Via GlobeNewswire
    Alector to Host Mid-Year Earnings Conference Call
    From Alector, Inc.
    Via GlobeNewswire
    Recap: Alector Q4 Earnings
    Via Benzinga
    Earnings Scheduled For February 27, 2024
    Via Benzinga
    Earnings Outlook For Alector
    Via Benzinga
    Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
    From Alector, Inc.
    Via GlobeNewswire
    Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024
    From Alector, Inc.
    Via GlobeNewswire
    Alector to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
    From Alector, Inc.
    Via GlobeNewswire
    Perion Network Cuts Revenue Outlook, Joins Skye Bioscience And Other Big Stocks Moving Lower In Monday's Pre-Market Session
    Via Benzinga
    Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform
    From Alector, Inc.
    Via GlobeNewswire
    Alector to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
    From Alector, Inc.
    Via GlobeNewswire
    Alector to Participate in Upcoming Healthcare Conferences
    From Alector, Inc.
    Via GlobeNewswire
    ALEC Stock Earnings: Alector Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Alector Reports First Quarter 2024 Financial Results and Provides Business Update
    From Alector, Inc.
    Via GlobeNewswire
    Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
    Via Investor's Business Daily
    Exposures Product Safety
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Via InvestorPlace
    Alector to Participate in Upcoming Healthcare Conferences
    From Alector, Inc.
    Via GlobeNewswire
    Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    From Alector, Inc.
    Via GlobeNewswire
    Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call
    From Alector, Inc.
    Via GlobeNewswire
    Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease
    From Alector, Inc.
    Via GlobeNewswire
    FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
    From Alector, Inc.
    Via GlobeNewswire
    Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs
    Via InvestorPlace
    Alector Announces Closing of Public Offering
    From Alector, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.